ADAMA (000553) Q4 2023 earnings summary

Executive summary

• FY2023 sales fell 16% YoY to $4,661m and adjusted EBITDA declined 45% to $407m amid channel destocking, pricing pressure and FX headwinds.

• Inventory reduction, OPEX controls and cash-flow actions supported liquidity and improved full-year operating cash flow.

• A transformation plan focuses on differentiated formulations, strategic crop segments, portfolio quality and cost-base improvement.

Financial highlights

• FY2023 sales were $4,661m versus $5,570m, down 16%; volume declined 7% and prices 8%, with FX also reducing sales.

• Q4 sales fell 13% to $1,136m, as prices declined 15% and volumes rose 1%.

• Adjusted EBITDA was $407m for FY versus $740m, and $95m in Q4 versus $129m; FY adjusted gross profit fell 32% to $1,060m.

• FY adjusted net loss was $236m versus net income of $118m; reported net loss was $225m versus net income of $96m. Q4 adjusted and reported net losses were $101m and $79m.

Outlook and guidance

• 2024 crop-protection market value was expected to decline on pricing; low-single-digit volume recovery was expected to offset sell-in pricing pressure.

• Channel inventories improved across most geographies entering 2024 but had not normalized everywhere.

• Priorities include value innovation, differentiated formulations, strategic crop segments, portfolio optimization, cost improvement and cash generation; transformation milestones were to be shared during 2024.

• Planned European launches include a cereal fungicide portfolio powered by Asorbital formulation technology.